MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Behavioral abnormalities"

  • 2019 International Congress

    The prevalence of ICBs in patients treated with apomorphine infusion: a retrospective analysis

    P. Barbosa, A. Lees, A. Djamshidian, T. Warner (Innsbruck, Austria)

    Objective: To assess the prevalence of impulsive compulsive behaviours (ICBs) in Parkinson’s disease who donated their brains and used apomorphine infusion in life. Background: Impulsive…
  • 2019 International Congress

    Parkinson’s disease polygenic risk score is not associated with impulse control disorders: a longitudinal study

    J. Ihle, F. Artaud, S. Bekadar, G. Magnone, H. Bertrand, S. Sambin, LL. Mariani, C. Scherzer, A. Elbaz, JC. Cornol (Paris, France)

    Objective: To examine the relationship between a polygenic risk score (GRS) associated with Parkinson’s disease (PD) and impulse control disorders (ICDs) in PD. Background: Genome…
  • 2019 International Congress

    Successful treatment of Parkinson’s disease-related impulse control disorder with bilateral STN DBS

    T. Stiep, D. Spengler Shpiner, C. Luca (Miami, FL, USA)

    Objective: To present a case of Parkinson’s disease (PD) complicated by impulse control disorder (ICD) which improved following deep brain stimulation (DBS) targeting the bilateral…
  • 2019 International Congress

    Protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease

    S. Rajput, S. Sinha (New Delhi, India)

    Objective: Objective of our study was to evaluate protective and therapeutic activity of Cinnamaldehyde in the mouse model of Parkinson’s disease. Background: Parkinson’s disease (PD),…
  • 2019 International Congress

    The Huntington’s Disease-Behavioral Questionnaire (HD-BQ): A New Screening Tool for Behavioral Disturbances in HD

    J. Corey-Bloom, S. Aboufadel, I. Beltran-Najera, C. Snell, M. Williams, P. Gilbert (La Jolla, CA, USA)

    Objective: To examine the usefulness of a new behavioral questionnaire for patients with, and at risk for, Huntington’s disease (HD). Background: Behavioral changes, including apathy,…
  • 2019 International Congress

    Professional characteristics of people with or without impulse control disorders in Parkinson’s disease from a single centre cohort study, Moscow, Russia

    N. Titova, N. Shipilova, E. Katunina (Moscow, Russian Federation)

    Objective: We analyzed professional activity in Parkinson’s disease (PD) patients with and without impulse control disorder (ICD) from a single center cohort study in Moscow,…
  • 2019 International Congress

    Assessment of Caregiver Burden in Huntington’s disease

    M. Yu, K. Tan, K. Koloms, D. Bega (Chicago, IL, USA)

    Objective: We aim to identify and characterize caregiver burden among HD caregivers, to see what aspects of HD caregiving are associated with the greatest burden…
  • 2019 International Congress

    Impulse Control Disorders in a Brazilian population with Parkinson´s disease -an observational study

    B. Veiga, V. Borges, H. Ferraz, C. Aquino, C. Giacominelli, SM. Silva, S. Lestingi (São Paulo, Brazil)

    Objective: To Analyse Impulse Control Disorders (ICDs) and Related Behaviors (RB) in 36 Brazilian patients with Parkinson´s disease (PD) and compare the cognition of the…
  • 2019 International Congress

    Behavioural aspect of transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by Ropinirole alginate nanocomposite

    F. Naz, R. X, YHS. Siddique (Aligarh, India)

    Objective: To evaluate the behavioural changes in transgenic Drosophila melanogaster as a model of Parkinson’s disease treated by different doses of Ropinirole alginate nanocomposite (RANC).…
  • 2019 International Congress

    Cognitive and psychiatric course in the initial lustrum of Parkinson disease: the glass is half full

    D. Weintraub, C. Caspell-Garcia, H. Cho, T. Simuni, A. Siderowf, C. Coffey, D. Aarsland, R. Alcalay, L. Chahine, J. Eberling, A. Espay, J. Hamilton, J. Leverenz, I. Litvan, I. Richard, L. Rosenthal, M. York (Philadelphia, PA, USA)

    Objective: To describe the cognitive-psychiatric course in the first 5 years of diagnosed Parkinson disease (PD). Background: Although common, little is known about the differential…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley